Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:NARINASDAQ:SSIINYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$97.69+0.1%$92.76$77.10▼$163.71$5.58B0.8725,877 shs797,572 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.37 million shsN/ASSIISS Innovations International$3.54-9.2%$0.00$0.32▼$22.42$755.06MN/A38,467 shs77,511 shsSTVNStevanato Group€23.40-2.5%€22.44€16.56▼€25.75$7.09B0.53337,852 shs466,100 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos+0.36%+5.00%+6.82%-4.63%-13.92%NARIInari Medical0.00%0.00%0.00%0.00%+70.58%SSIISS Innovations International-9.23%-41.00%-64.78%+353,999,900.00%+353,999,900.00%STVNStevanato Group-1.89%-1.68%-1.52%+17.71%+26.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.4155 of 5 stars4.42.00.04.41.62.50.6NARIInari Medical0.4738 of 5 stars1.10.00.00.01.52.50.6SSIISS Innovations InternationalN/AN/AN/AN/AN/AN/AN/AN/ASTVNStevanato Group1.7271 of 5 stars0.04.01.70.01.60.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6737.85% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideSSIISS Innovations International 0.00N/AN/AN/ASTVNStevanato Group 2.86Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest SSII, STVN, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.004/21/2025STVNStevanato GroupStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025GKOSGlaukosMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$200.00 ➝ $175.004/15/2025GKOSGlaukosPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$180.00 ➝ $165.004/11/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$185.00 ➝ $140.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$404.52M13.80N/AN/A$9.46 per share10.33NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91SSIISS Innovations International$22.13M30.97N/AN/AN/A∞STVNStevanato Group$1.12B6.30€0.98 per share23.97€4.15 per share5.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ASSIISS Innovations InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ASTVNStevanato Group$157.62M€0.5149.7940.347.1810.47%9.86%5.79%N/ALatest SSII, STVN, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/ASTVNStevanato Group€0.060.26%N/A11.76%1 YearsLatest SSII, STVN, GKOS, and NARI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.195.544.71NARIInari MedicalN/A1.771.40SSIISS Innovations InternationalN/AN/AN/ASTVNStevanato Group0.221.811.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%NARIInari Medical90.98%SSIISS Innovations InternationalN/ASTVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%NARIInari Medical10.60%SSIISS Innovations InternationalN/ASTVNStevanato Group0.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million51.61 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableSSIISS Innovations International4193.60 millionN/AN/ASTVNStevanato Group4,650302.84 million300.72 millionOptionableSSII, STVN, GKOS, and NARI HeadlinesRecent News About These CompaniesStevanato Group (NYSE:STVN) Shares Down 4.7% - Here's What HappenedJune 12 at 4:58 PM | marketbeat.comSubcontractor sues for nearly $1.6M in unpaid work on Stevanato site in FishersJune 12 at 12:50 PM | theindianalawyer.comYarbrough Capital LLC Acquires Shares of 16,113 Stevanato Group S.p.A. (NYSE:STVN)June 8, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 6, 2025 | americanbankingnews.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 6, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Short Interest UpdateJune 5, 2025 | marketbeat.comEx-Dividend Reminder: Stevanato Group SpA, Golden Ocean Group and Flowers FoodsJune 4, 2025 | nasdaq.comWellington Management Group LLP Trims Position in Stevanato Group S.p.A. (NYSE:STVN)June 4, 2025 | marketbeat.comGRFS vs. STVN: Which Stock Is the Better Value Option?June 2, 2025 | zacks.comStevanato Group S.p.A. (STVN): A Bull Case TheoryMay 30, 2025 | msn.comD. E. Shaw & Co. Inc. Takes Position in Stevanato Group S.p.A. (NYSE:STVN)May 29, 2025 | marketbeat.comBank of America Corp DE Sells 77,677 Shares of Stevanato Group S.p.A. (NYSE:STVN)May 29, 2025 | marketbeat.comNorthern Trust Corp Decreases Stock Position in Stevanato Group S.p.A. (NYSE:STVN)May 28, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $1.06 Million in Stevanato Group S.p.A. (NYSE:STVN)May 23, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Stock Position Increased by Silvercrest Asset Management Group LLCMay 21, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Shares Acquired by Ameriprise Financial Inc.May 21, 2025 | marketbeat.comThornburg Investment Management Inc. Grows Stock Holdings in Stevanato Group S.p.A. (NYSE:STVN)May 20, 2025 | marketbeat.comPolar Capital Holdings Plc Has $19.06 Million Position in Stevanato Group S.p.A. (NYSE:STVN)May 18, 2025 | marketbeat.comLMR Partners LLP Takes $413,000 Position in Stevanato Group S.p.A. (NYSE:STVN)May 17, 2025 | marketbeat.comDeutsche Bank AG Lowers Stake in Stevanato Group S.p.A. (NYSE:STVN)May 17, 2025 | marketbeat.comLazard Asset Management LLC Sells 649,073 Shares of Stevanato Group S.p.A. (NYSE:STVN)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSSII, STVN, GKOS, and NARI Company DescriptionsGlaukos NYSE:GKOS$97.69 +0.09 (+0.09%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$97.77 +0.08 (+0.08%) As of 06/13/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.SS Innovations International NASDAQ:SSII$3.54 -0.36 (-9.23%) As of 06/13/2025 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.Stevanato Group NYSE:STVN€23.40 -0.60 (-2.50%) As of 06/13/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
